# Administrative, Biostatistics and GLP Management Core (ABGMC)

> **NIH NIH U19** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $354,791

## Abstract

PROJECT SUMMARY
 Over the past four years, our U19 AG060917 has evolved from being multi–disciplinary to a
transdisciplinary program that has begun to enable team science encompassing aging epidemiology, bone
biology, adipose tissue biology and the neurosciences. Based at three primary sites in the U.S.––Icahn School
of Medicine at Mount Sinai, Maine Medical Center Research Institute, and University of California at San
Francisco––the U19 receives collaborative input from Harvard Medical School, U.S. Department of Agriculture,
University of Leiden, Icelandic Heart Association, Columbia University, and, importantly, the National Institute
on Aging. The overall thrust that now integrates disciplines ranging from physical chemistry, biochemistry and
pharmacology, to complex mouse genetics, to case–cohort studies in people necessitates a mechanism that
will not only maintain connectivity between the groups over time, but also, more importantly, enable true
synergy. Thus, one function of the Administrative, Biostatistical and GLP Management Core (Core C) is to
provide overarching leadership, coordination and support across all sites. This has already been achieved
under the joint leadership of Drs. Zaidi and Rosen and will continue in earnest. For further seamlessness,
Core C has put in place a purposefully–crafted administrative structure for budget management, personnel
management, general scheduling and communication, and record maintenance. Dedicated biostatistical
support will ensure conformity of statistical procedures across multiple sites, and together with the MediaLab
Document Control System (Core A), will facilitate data re–analysis and cross–institutional validation. For
Projects that require analysis or re–analysis of RNA sequencing data, Core C will provide bioinformatics
support. Finally, we have recently expanded Core C to include the management of our new Good Laboratory
Practice (GLP) Platform. This platform has a separate GLP lab, is supported by an independent Quality
Assurance Program, and complies with the Code of Federal Regulations, Title 21, Part 58. The platform will
allow the proposed studies to be carried out under the strictest standards––which we consider not only a step
forward towards full transparency and rigor but is also key to the movement of our therapeutic FSH–blocking
antibody, MS-Hu6, into the clinic. In all, Core C, which is now matrixed within the Center for Translational
Medicine and Pharmacology of which Dr. Zaidi is Director, has become a vital overarching component of all
U19 Projects and both Cores.

## Key facts

- **NIH application ID:** 10764101
- **Project number:** 2U19AG060917-06
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Mone Zaidi
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $354,791
- **Award type:** 2
- **Project period:** 2019-02-01 → 2029-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10764101

## Citation

> US National Institutes of Health, RePORTER application 10764101, Administrative, Biostatistics and GLP Management Core (ABGMC) (2U19AG060917-06). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10764101. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*